The Pancreatic Cancer Action Network Selects Oncolytics Biotech^® Inc. to Receive $5 Million Therapeutic Accelerator Award to Develop Leading-Edge Treatments

The $5 million grant will enable Oncolytics to continue the next stage of its research focused on a clinical trial with Oncolytics’ proprietary reovirus pelareorep in combination with modified FOLFIRINOX chemotherapy, with or without an immune checkpoint inhibitor.